The BioMed X Institute
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
HEIDELBERG, GERMANY / ACCESSWIRE / December 19, 2023 / BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan. The project entitled "New Strategies to Engage Neutrophils in Solid Tumors" will be hosted by the BioMed X Institute in Heidelberg, Germany. The goal of this research project is to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.
Developing immunotherapies that target T cells has proved highly effective, and it is still a rapidly evolving research area. However, many patients remain resistant to these therapies, necessitating the development of novel immunological strategies. The presence of neutrophils in solid tumors has been well-documented, albeit their role in the tumor microenvironment seems to be paradoxical according to the data accumulated thus far. By uncovering novel neutrophil biology, this project aims to leverage their functions to design novel immunotherapies.
The new research team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C03 before February 18, 2024.
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "Oncology and immunology, including tumor immunology, are key areas of expertise at BioMed X. We are proud and honored that Ono has chosen our institute to develop new strategies for engaging neutrophils in cancer therapy".
Toichi Takino, Senior Executive Officer/Executive Director, Discovery & Research at Ono Pharmaceutical: "We are very pleased to form a partnership with BioMed X in our mission dedicated to overcoming cancer. This innovative research collaboration will engage us with highly talented scientists around the world who possess unique ideas for immunotherapy utilizing neutrophils. We believe that the research team established through this collaboration will lead to the discovery of the next generation of immunotherapy with us".
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
About Ono
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company's website at https://www.ono-pharma.com/en.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
View the original press release on newswire.com.
SOURCE: BioMed X Institute
To view this piece of content from stats.newswire.com, please give your consent at the top of this page. To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Announced The Completion of its Acquisition of LMB Fans & Motors26.12.2025 14:00:00 CET | Press release
WHITE PLAINS, NEW YORK / ACCESS Newswire / December 26, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar," "we," "our," or "the Company") today announced the completion of its acquisition of LMB Fans & Motors ("LMB") for €367 million, plus the assumption of debt, paid in cash at closing. Founded more than 60 years ago, LMB is a global leader in designing and manufacturing customized, high-performance fans and motors. With decades of expertise and nearly 100% of its revenue derived from proprietary designs, LMB offers over 2,000 unique products, including fans, blowers, motors, and specialized rotating machines. Its fans and brushless motors are widely used across aerospace and defense platforms. LMB employs more than 75 team members worldwide, including those at its headquarters and manufacturing facility in Malemort-sur-Corrèze, France. The transaction was completed following clearance under the French foreign direct investment screening procedure by the Ministry of Economy and Finance. L
SK tes Announces Grand Opening of New Shannon Facility, Marking a Milestone for Sustainable Technology in Ireland22.12.2025 15:00:00 CET | Press release
SHANNON, IE / ACCESS Newswire / December 22, 2025 / SK tes, a global leader in secure technology lifecycle and IT asset disposition (ITAD) services, is delighted to announce the grand opening of its state-of-the-art facility in Shannon, County Clare. The opening event, to be held on Jan. 15, 2026, marks the culmination of a journey that began with the company's announcement in 2025 of its plans to establish a purpose-built facility in one of Ireland's fastest-growing technology regions. The grand opening will be hosted by Jin Mo Lee, SK tes Group CEO at SK tes and guest of honor, Minister Timmy Dooley will cut the ribbon to officially open the site. Minister Dooley, a Clare native, serves as Minister of State for Climate, Energy and the Environment. Minister Dooley's leadership in climate, energy, and environmental policy is especially relevant as Ireland continues to attract major global data center infrastructure and technology companies, while placing increased emphasis on sustainab
Saat & Saat Acquires Turkish Apparel Leader Aydinli Group, Expanding U.S. Polo Assn. Markets Across Turkey, the Middle East, Eastern Europe, and North Africa22.12.2025 13:00:00 CET | Press release
WEST PALM BEACH, FL AND ISTANBUL, TURKEY / ACCESS Newswire / December 22, 2025 / USPA Global is pleased to announce the acquisition of Aydinli Hazir Giyim San. Tic. A.S. (Aydinli Group) by HRK Holding A.S. (Saat & Saat). Both entities are licensing partners of U.S. Polo Assn., which is USPA Global's multi-billion-dollar sports brand and the official brand of the United States Polo Association (USPA). As one of the brand's largest partners, the acquisition of Aydinli provides access to more than 50 countries across Turkey, the Middle East, Eastern Europe, and North Africa. With this acquisition of Aydinli, Saat & Saat is expanding the company's regional portfolio alongside its very successful watch business by entering the global apparel industry. With more than nearly 450 U.S. Polo Assn. stores and multiple branded digital sites, U.S. Polo Assn. will continue its record growth. Aydinli is currently one of the leading retail powerhouses in the region, with significant growth potential a
Parallel Society Reveals Lineup for 2026 Lisbon Edition - A Cross-Genre Mashup of Cultural and Tech Pioneers22.12.2025 10:30:00 CET | Press release
Apparat (live) Kode9, Moses Boyd, Gilles Peterson and Clark head to Lisbon for new indie festival Parallel Society. LISBON, PT / ACCESS Newswire / December 22, 2025 / Parallel Society has revealed the first wave of artists for its 2026 edition in Lisbon, Portugal. The two-day event begins on 6th March, and the music starts on 7th March with a programme spanning the UK jazz revolution (Moses Boyd), experimental bass culture (Kode9, Calibre), avant-electronic (Apparat), and cultural ambassadors (Gilles Peterson), with many more acts still to be announced. A culture-first counterpoint to the corporate consolidation sweeping the global festival landscape, Parallel Society is independent, led by the community, and not for profit. With more than 60% of the lineup sourced from Lisbon's active and diverse homegrown talent pool, the event actively supports the city's underground music scenes. Ahead of Parallel Society's music and cultural programme on Day 2, Day 1, the "[un]conference", invites
Rainer Maria Morita Named "Transformational Leader of the Year 2025" at UK House of Lords22.12.2025 10:25:00 CET | Press release
Recognized for redefining executive career transition and human value creation in the AI era with his globally renowned Morita Method(R) LONDON, GB / ACCESS Newswire / December 22, 2025 / Global executive advisor and bestselling author, Rainer Maria Morita, has been awarded "Transformational Leader of the Year 2025 in the category of Global Hidden Job Market Advisory at the prestigious Global Leadership Conclave 2025, held at the iconic UK House of Lords, Parliament of the United Kingdom. The award recognizes Rainer's pioneering work in redefining leadership, employment, and human value creation in the age of artificial intelligence. With more than two decades of experience across executive search, executive career transition advisory and leadership consulting, Rainer has become a globally respected authority on the Hidden Job Market - the unadvertised ecosystem where over 90% of executive opportunities are created. As the creator of The Morita Method®, Rainer has guided thousands of s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom